LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
33.91
-0.74 (-2.14%)
Nov 20, 2024, 4:00 PM EST - Market closed

LENZ Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21
Revenue
--15-
Gross Profit
--15-
Selling, General & Admin
24.9112.934.362.47
Research & Development
43.4759.521.134.22
Operating Expenses
68.3772.4325.486.69
Operating Income
-68.37-72.43-10.48-6.69
Interest & Investment Income
6.842.190-
Other Non Operating Income (Expenses)
0.550.090.02-0.87
Pretax Income
-60.99-70.15-10.46-7.56
Income Tax Expense
-0.18-0.180.35-
Net Income
-60.81-69.97-10.81-7.56
Net Income to Common
-60.81-69.97-10.81-7.56
Shares Outstanding (Basic)
231099
Shares Outstanding (Diluted)
231099
Shares Change (YoY)
486.94%2.47%1.05%-
EPS (Basic)
-2.69-7.22-1.14-0.81
EPS (Diluted)
-2.69-7.22-1.14-0.81
Free Cash Flow
-71.6-60.41-4.13-5.4
Free Cash Flow Per Share
-3.17-6.23-0.44-0.58
Gross Margin
--100.00%-
Operating Margin
---69.89%-
Profit Margin
---72.07%-
Free Cash Flow Margin
---27.52%-
EBITDA
-68.34-72.41-10.48-6.69
EBITDA Margin
---69.83%-
D&A For EBITDA
0.040.020.010
EBIT
-68.37-72.43-10.48-6.69
EBIT Margin
---69.89%-
Revenue as Reported
--15-
Source: S&P Capital IQ. Standard template. Financial Sources.